source
- Sanofi pauses Phase 2 bronchiectasis study of SAR445399 amid new CEO’s portfolio reviewSanofi has halted a Phase 2 trial of its investigational antibody SAR445399 in non‑cystic fibrosis bronchiectasis. The pause was attributed to strategic business reasons linked to an internal portf…
- BioVie’s Parkinson drug data prompts 50% stock drop as company shifts to composite endpointBioVie announced phase 2 results for its experimental Parkinson’s therapy bezisterim, saying the data suggest a meaningful advance in treating the disease. Investors reacted sharply, wiping out ro…